Loading: 100%
PEREGRINE PHARMACEUTICALS INC logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees 323 (as per Q2 2017)no data available
Sector Biotechnology, HealthcareBiotechnology, Healthcareno data available
Ticker PPHMno data available
Financial year endsFY ends End of Aprilno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 170,01,53,04,56,0
datesClosing price (adj.)
13.10.20173.83
11.10.20173.70
04.10.20173.31
27.09.20173.14
20.09.20173.12
13.09.20173.02
06.09.20173.12
30.08.20173.23
23.08.20173.11
16.08.20173.20
09.08.20173.87
02.08.20174.26
26.07.20174.30
19.07.20175.20
12.07.20174.79
05.07.20174.44
27.06.20173.95
20.06.20173.99
13.06.20173.85
06.06.20174.10
30.05.20173.86
23.05.20173.90
16.05.20174.24
09.05.20174.25
02.05.20174.39
25.04.20174.14
18.04.20173.80
11.04.20174.03
04.04.20174.43
28.03.20174.90
21.03.20175.01
14.03.20174.97
07.03.20174.85
28.02.20174.24
21.02.20173.35
14.02.20172.61
07.02.20172.27
31.01.20172.10
24.01.20172.14
17.01.20172.03
10.01.20172.08
03.01.20172.12
27.12.20162.50
19.12.20162.23
12.12.20162.59
05.12.20162.16
28.11.20162.11
21.11.20162.21
14.11.20162.36
07.11.20162.13
31.10.20162.36
24.10.20162.50
17.10.20162.35
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
3.83n/a
Market Capitalisation
in million USD
135n/a
Enterprise Value
in million USD
86n/a
Common Shares Outstanding
as per Oct 31, 2016
35,247,139n/a
Preferred Shares Outstanding
as per Oct 31, 2016
230,686n/a
Average Basic Shares Outstanding
TTM
237,053,388n/a
Average Diluted Shares Outstanding
TTM
n/a
Index Membership
n/a
Business Summary
Peregrine Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It develops novel investigational products that help utilize the immune system to fight cancer, also known as immunotherapy.
no data available
Key Financials & Ratios (all figures TTM as per Oct 31, 2016, million USD, full statements further below)
Profit & Loss
Revenues 54n/a
Gross Profit 22n/a
Operating Income -44n/a
EBITDA -42n/a
Net Profit -48n/a
Balance Sheet
Cash and Cash Equivalents 49n/a
Receivables 0n/a
Total Current Assets 83n/a
PP&E 24n/a
Total Assets 110n/a
Accounts Payable 12n/a
Current Debt 0n/a
Total Current Liabilities 66n/a
Long-Term Debt 0n/a
Total Liabilities 68n/a
Total Equity 42n/a
Cash Flow
Depreciation & Amortisation 2n/a
Change in Working Capital 7n/a
Operating Cash Flow -31n/a
Net Change in PP&E and Intangibles -6n/a
Investing Cash Flow -5n/a
Dividends Paid -4n/a
Financing Cash Flow 13n/a
Total Change in Cash -23n/a
Free Cash Flow -40n/a
Profitability Ratios
Gross Margin 41.0%n/a
Operating Margin -80.7%n/a
Net Profit Margin -80.5%n/a
Return on Equity -104.0%n/a
Return on Assets -39.9%n/a
Per Share Figures
Basic EPS -0.20n/a
Diluted EPS n/a
Sales per Share 0.23n/a
Book Value per Share 0.18n/a
FCF per Share -0.17n/a
Dividends per Share 0.02n/a
Price Multiples
Price to Earnings Ratio -18.90n/a
Price to Sales Ratio 16.67n/a
Price to Book Value 21.53n/a
Price to Free Cash Flow -22.63n/a
Valuation Metrics
EV/EBITDA -2.06n/a
EV/Sales 1.58n/a
Book to Market Value 0.31n/a
Other Ratios
Current Ratio 124.6%n/a
Liabilities to Equity Ratio 160.6%n/a
Debt to Assets Ratio 0.0%n/a
Profit & Loss StatementP&L data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Revenue
28
13
15
22
22
27
45
Sales & Services Revenue
0
0
0
0
0
0
0
Financing Revenue
0
0
0
0
0
0
0
Other Revenue
0
0
0
0
0
0
0
Cost of revenue
-9
-7
-10
-13
-13
-16
-23
Cost of Goods & Services
0
0
0
0
0
0
0
Cost of Financing Revenue
0
0
0
0
0
0
0
Cost of Other Revenue
0
0
0
0
0
0
0
Gross Profit
19
6
5
9
9
11
22
Other Operating Income
0
0
0
0
0
0
0
Operating Expenses
-33
-41
-47
-37
-45
-62
-78
Selling, General & Administrative
-8
-11
-11
-13
-17
-19
-19
Selling & Marketing
0
0
0
0
0
0
0
General & Administrative
0
0
0
0
0
0
0
Research & Development
-25
-29
-36
-24
-28
-43
-60
Depreciation & Amortization
0
0
0
0
0
0
0
Provision For Doubtful Accounts
0
0
0
0
0
0
0
Other Operating Expense
0
0
0
0
0
0
0
Operating Income (Loss)
-14
-35
-42
-28
-36
-50
-56
Non-Operating Income (Loss)
-1
1
0
0
0
0
1
Interest Expense, net
0
0
0
0
0
0
0
Interest Expense
0
0
0
0
0
0
0
Interest Income
0
0
0
0
0
0
0
Other Investment Income (Loss)
0
0
0
0
0
0
0
Foreign Exchange Gain (Loss)
0
0
0
0
0
0
0
Income (Loss) from Affiliates
0
0
0
0
0
0
0
Other Non-Operating Income (Loss)
-1
1
0
0
0
0
1
Pretax Income (Loss), Adjusted
-14
-34
-42
-28
-35
-50
-56
Abnormal Gains (Losses)
0
0
0
-2
0
0
0
Acquired In-Process R&D
0
0
0
0
0
0
0
Merger / Acquisition Expense
0
0
0
0
0
0
0
Abnormal Derivatives
0
0
0
0
0
0
0
Disposal of Assets
0
0
0
0
0
0
0
Early extinguishment of Debt
0
0
0
0
0
0
0
Asset Write-Down
0
0
0
0
0
0
0
Impairment of Goodwill & Intangibles
0
0
0
0
0
0
0
Sale of Business
0
0
0
0
0
0
0
Legal Settlement
0
0
0
0
0
0
0
Restructuring Charges
0
0
0
0
0
0
0
Sale of and Unrealized Investments
0
0
0
0
0
0
0
Insurance Settlement
0
0
0
0
0
0
0
Other Abnormal Items
0
0
0
0
0
0
0
Pretax Income (Loss)
-14
-34
-42
-30
-35
-50
-56
Income Tax (Expense) Benefit, net
0
0
0
0
0
0
0
Current Income Tax
0
0
0
0
0
0
0
Deferred Income Tax
0
0
0
0
0
0
0
Tax Allowance/Credit
0
0
0
0
0
0
0
Income (Loss) from Affiliates, net of taxes
0
0
0
0
0
0
0
Income (Loss) from Continuing Operations
-14
-34
-42
-30
-35
-50
-56
Net Extraordinary Gains (Losses)
0
0
0
0
0
0
0
Discontinued Operations
0
0
0
0
0
0
0
XO & Accounting Charges & Other
0
0
0
0
0
0
0
Income (Loss) Including Minority Interest
-14
-34
-42
-30
-35
-50
-56
Minority Interest
0
0
0
0
0
0
0
Net Income
-14
-34
-42
-30
-35
-50
-56
Preferred Dividends
0
0
0
0
0
-4
-4
Other Adjustments
0
0
0
0
0
0
0
Net Income Available to Common Shareholders
-14
-34
-42
-30
-36
-54
-60
Remarks
restated on Jul 16, 2012 n/a
calculated values,
restated on Jul 11, 2013 n/a
calculated values,
restated on Jul 14, 2014 n/a
calculated values,
restated on Jul 14, 2015 n/a
calculated values,
restated on Jul 14, 2016 n/a
calculated values,
restated on Jul 14, 2016 n/a
calculated values,
restated on Jul 14, 2016 n/a
calculated values,
Balance SheetBS data quality: 98% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Assets
Cash, Cash Equivalents & Short Term Investments
n/a
23
18
35
77
68
61
Cash & Cash Equivalents
n/a
23
18
35
77
68
61
Short Term Investments
n/a
0
0
0
0
0
0
Accounts & Notes Receivable
n/a
1
2
2
1
4
3
Accounts Receivable, Net
n/a
0
0
0
0
0
0
Notes Receivable, Net
n/a
0
0
0
0
0
0
Unbilled Revenues
n/a
0
0
0
0
0
0
Inventories
n/a
5
4
4
6
7
16
Raw Materials
n/a
0
0
0
0
0
0
Work In Process
n/a
0
0
0
0
0
0
Finished Goods
n/a
0
0
0
0
0
0
Other Inventory
n/a
0
0
0
0
0
0
Other Short Term Assets
n/a
1
1
1
1
1
1
Prepaid Expenses
n/a
1
1
1
1
1
1
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
Assets Held-for-Sale
n/a
0
0
0
0
0
0
Deferred Tax Assets
n/a
0
0
0
0
0
0
Income Taxes Receivable
n/a
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
Miscellaneous Short Term Assets
n/a
0
0
0
0
0
0
Total Current Assets
n/a
31
25
42
86
81
82
Property, Plant & Equipment, Net
n/a
2
3
3
2
3
24
Property, Plant & Equipment
n/a
7
9
9
10
11
0
Accumulated Depreciation
n/a
-5
-6
-7
-7
-8
0
Long Term Investments & Receivables
n/a
0
0
0
0
0
0
Long Term Investments
n/a
0
0
0
0
0
0
Long Term Marketable Securities
n/a
0
0
0
0
0
0
Long Term Receivables
n/a
0
0
0
0
0
0
Other Long Term Assets
n/a
2
1
0
2
2
3
Intangible Assets
n/a
0
0
0
0
0
0
Goodwill
n/a
0
0
0
0
0
0
Other Intangible Assets
n/a
0
0
0
0
0
0
Prepaid Expense
n/a
0
0
0
0
0
0
Deferred Tax Assets
n/a
0
0
0
0
0
0
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
Prepaid Pension Costs
n/a
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
Investments in Affiliates
n/a
0
0
0
0
0
0
Miscellaneous Long Term Assets
n/a
2
1
0
2
2
3
Total Noncurrent Assets
n/a
4
3
3
5
5
27
Total Assets
n/a
35
28
45
91
86
109
Liabilities and owners' equity
Payables & Accruals
n/a
8 7793000
8 8071000
7 7333000
11 10704000
19 18901000
22 21844000
Accounts Payable
n/a
4 4046000
3 3492000
3 2821000
2 2434000
10 10385000
8 8429000
Accrued Taxes
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Interest & Dividends Payable
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Payables & Accruals
n/a
4 3747000
5 4579000
5 4512000
8 8270000
9 8516000
13 13415000
Short Term Debt
n/a
1 1321000
0 0
0 0
0 0
0 0
0 0
Short Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Short Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Current Portion of Long Term Debt
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Short Term Liabilities
n/a
9 8565000
10 9568000
13 13228000
12 11503000
18 18430000
36 35730000
Deferred Revenue
n/a
6 5617000
4 3651000
4 4171000
5 5241000
7 6630000
10 10030000
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Short Term Liabilities
n/a
3 2948000
6 5917000
9 9057000
6 6262000
12 11800000
26 25700000
Total Current Liabilities
n/a
18 17679000
18 17639000
21 20561000
22 22207000
37 37331000
58 57574000
Long Term Debt
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Long Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Long Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Long Term Liabilities
n/a
2 1669000
1 1140000
1 737000
1 639000
1 1098000
1 1395000
Accrued Liabilities
n/a
0 0
0 0
0 0
0 347000
1 1098000
1 1395000
Pension Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Pensions
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Post-Retirement Benefits
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Compensation
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Revenue
n/a
1 632000
0 361000
0 292000
0 292000
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Long Term Liabilities
n/a
1 1037000
1 779000
0 445000
0 0
0 0
0 0
Total Noncurrent Liabilities
n/a
2 1669000
1 1140000
1 737000
1 639000
1 1098000
1 1395000
Total Liabilities
n/a
19 19348000
19 18779000
21 21298000
23 22846000
38 38429000
59 58969000
Preferred Equity
n/a
0 0
0 0
0 0
0 1000
0 2000
0 2000
Share Capital & Additional Paid-In Capital
n/a
311 311423000
348 347607000
392 391664000
471 470964000
513 512657000
559 559348000
Common Stock
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Additional Paid in Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Share Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Treasury Stock
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Retained Earnings
n/a
-296 -296005000
-338 -338124000
-368 -367904000
-403 -403266000
-454 -453624000
-509 -509276000
Other Equity
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Equity Before Minority Interest
n/a
15 15418000
9 9483000
24 23760000
68 67699000
59 59035000
50 50074000
Minority Interest
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Total Equity
n/a
15 15418000
9 9483000
24 23760000
68 67699000
59 59035000
50 50074000
Total Liabilities & Equity
n/a
35 34766000
28 28262000
45 45058000
91 90545000
97 97464000
109 109043000
Remarks restated on n/a restated on Jul 16, 2012 n/a restated on Jul 11, 2013 n/a restated on Jul 14, 2014 n/a restated on Jul 14, 2015 n/a restated on Jul 14, 2016 n/a restated on Dec 12, 2016 n/a
Cash Flow StatementCF data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Net Income/Starting Line
-14
-34
-42
-30
-35
-50
-56
Net Income
0
0
0
0
0
0
0
Net Income From Discontinued Operations
0
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
Depreciation & Amortization
0
1
1
1
1
1
2
Non-Cash Items
-2
4
3
5
6
7
4
Stock-Based Compensation
0
0
0
0
0
0
0
Deferred Income Taxes
0
0
0
0
0
0
0
Other Non-Cash Adjustments
0
0
0
0
0
0
0
Change in Working Capital
2
3
3
3
0
7
10
(Increase) Decrease in Accounts Receivable
0
0
0
0
0
0
0
(Increase) Decrease in Inventories
0
0
0
0
0
0
0
Increase (Decrease) in Accounts Payable
0
0
0
0
0
0
0
Increase (Decrease) in Other
0
0
0
0
0
0
0
Net Cash From Discontinued Operations (operating)
0
0
0
0
0
0
0
Cash from Operating Activities
-14
-26
-36
-21
-28
-36
-40
Change in Fixed Assets & Intangibles
0
-1
-2
-1
-1
-9
-9
Disposition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
Disposition of Fixed Assets
0
0
0
0
0
0
0
Disposition of Intangible Assets
0
0
0
0
0
0
0
Acquisition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
Purchase of Fixed Assets
0
0
0
0
0
0
0
Acquisition of Intangible Assets
0
0
0
0
0
0
0
Other Change in Fixed Assets & Intangibles
0
0
0
0
0
0
0
Net Change in Long Term Investment
0
0
0
0
0
0
0
Decrease in Long Term Investment
0
0
0
0
0
0
0
Increase in Long Term Investment
0
0
0
0
0
0
0
Net Cash From Acquisitions & Divestitures
0
0
0
0
0
0
0
Net Cash from Divestitures
0
0
0
0
0
0
0
Cash for Acqusition of Subsidiaries
0
0
0
0
0
0
0
Cash for Joint Ventures
0
0
0
0
0
0
0
Net Cash from Other Acquisitions
0
0
0
0
0
0
0
Other Investing Activities
0
0
0
0
-2
1
1
Net Cash From Discontinued Operations (investing)
0
0
0
0
0
0
0
Cash from Investing Activities
0
-1
-1
-1
-3
-8
-9
Dividends Paid
0
0
0
0
0
-3
-4
Cash From (Repayment of) Debt
-2
-2
-1
0
0
0
0
Cash From (Repayment of) Short Term Debt, net
0
0
0
0
0
0
0
Cash From (Repayment of) Long Term Debt, net
0
0
0
0
0
0
0
Repayments of Long Term Debt
0
0
0
0
0
0
0
Cash From Long Term Debt
0
0
0
0
0
0
0
Cash From (Repurchase of) Equity
26
33
33
40
73
38
46
Increase in Capital Stock
26
33
33
40
73
38
46
Decrease in Capital Stock
0
0
0
0
0
0
0
Other Financing Activities
0
0
0
-1
0
0
0
Net Cash From Discontinued Operations (financing)
0
0
0
0
0
0
0
Cash from Financing Activities
24
31
32
39
73
35
42
Net Cash Before Disc. Operations and FX
10
3
-5
17
42
-9
-7
Change in Cash from Disc. Operations and Other
0
0
0
0
0
0
0
Net Cash Before FX
10
3
-5
17
42
-9
-7
Effect of Foreign Exchange Rates
0
0
0
0
0
0
0
Net Changes in Cash
10
3
-5
17
42
-9
-7
Remarks
restated on Jul 16, 2012 n/a
calculated values,
restated on Jul 11, 2013 n/a
calculated values,
restated on Jul 14, 2014 n/a
calculated values,
restated on Jul 14, 2015 n/a
calculated values,
restated on Jul 14, 2016 n/a
calculated values,
restated on Jul 14, 2016 n/a
calculated values,
restated on Jul 14, 2016 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo